<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984619</url>
  </required_header>
  <id_info>
    <org_study_id>MYO-0834</org_study_id>
    <nct_id>NCT01984619</nct_id>
  </id_info>
  <brief_title>Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles</brief_title>
  <official_title>A Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles Utilizing the Iovera With Blunt Tip Cannula Smart Tip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira CryoTech, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira CryoTech, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the iovera° device with the blunt tip cannula for&#xD;
      the treatment of forehead wrinkles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wrinkle severity when eyebrows are elevated at 30 days post-treatment.</measure>
    <time_frame>120 Days</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Anticipated observations, adverse events and SAEs/UADEs will be assessed at each visit.</measure>
    <time_frame>120 Days</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">47</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Blunt Tip Cannula</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryotherapy for the utilization of wrinkle reduction (iovera)</intervention_name>
    <arm_group_label>Blunt Tip Cannula</arm_group_label>
    <other_name>iovera</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects, male or female, age 18 - 65 with forehead wrinkles deemed significant per&#xD;
        protocol inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Females 18-65 years of age.&#xD;
&#xD;
          -  Forehead wrinkle(s) rating of at least 2 in animation on the 5-point Wrinkle Scale&#xD;
             (5WS) which upon physical manipulation of the skin demonstrates a reduction in wrinkle&#xD;
             severity.&#xD;
&#xD;
          -  Subject has at least a 2 point difference between resting and dynamic forehead wrinkle&#xD;
             scores using the 5WS.&#xD;
&#xD;
          -  Glabellar wrinkle score of &quot;1&quot; or higher in animation on the 5-point Glabella Scale&#xD;
             (5GS).&#xD;
&#xD;
          -  Fitzpatrick Skin Type I, II, III, or IV.&#xD;
&#xD;
          -  Subject has consented and agreed to participate in all study procedures and visits for&#xD;
             the study's duration.&#xD;
&#xD;
          -  Subject is in good general health, free of any disease state, or physical condition&#xD;
             that might impair evaluation of forehead and/or glabellar wrinkle rating or which, in&#xD;
             the Investigator's opinion, exposes the subject to an unacceptable risk by study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a clotting disorder or coagulopathy that requires use of an anticoagulant&#xD;
             and/or antiplatelet therapy (e.g., warfarin, clopidigrel, etc.)&#xD;
&#xD;
          -  Subject has used medication or supplements affecting clotting cascade (e.g., aspirin,&#xD;
             fish oil, etc.), or non-steroidal anti-inflammatory drugs (NSAIDs, e.g., ibuprofen and&#xD;
             naproxen) within seven (7) days prior to administration of the device.&#xD;
&#xD;
          -  Subject has had prior surgery that alters the subcutaneous anatomy of the target&#xD;
             treatment sites.&#xD;
&#xD;
          -  Subject has undergone another surgical cosmetic procedure or botulinum toxin injection&#xD;
             at or above the level of the zygoma (cheekbones) within the past six (6) months prior&#xD;
             to administration of the device.&#xD;
&#xD;
          -  Subject has a resting wrinkle score of &quot;3&quot; or higher on the 5WS.&#xD;
&#xD;
          -  Subjects who actively elevate forehead at rest.&#xD;
&#xD;
          -  Subject has been treated with fillers in the temple or forehead area in the time&#xD;
             intervals specified prior to the start of their participation in the study.&#xD;
&#xD;
          -  Subject has any of the following:&#xD;
&#xD;
               1. Dermatochalasis with &lt;1mm lid margin when looking straight ahead.&#xD;
&#xD;
               2. Excessive skin laxity.&#xD;
&#xD;
               3. Asymmetry in the upper face.&#xD;
&#xD;
               4. History of facial nerve palsy.&#xD;
&#xD;
               5. Eyebrow or eyelid ptosis.&#xD;
&#xD;
               6. History of neuromuscular disorder.&#xD;
&#xD;
               7. Chronic dry eye symptoms.&#xD;
&#xD;
               8. Allergy or intolerance to local anesthetic agents (e.g., Lidocaine).&#xD;
&#xD;
               9. Use of narcotic medication for a chronic pain condition.&#xD;
&#xD;
              10. Any other clinically significant, in the opinion of the Investigator, local skin&#xD;
                  condition (e.g., skin infection) at target treatment site that may interfere or&#xD;
                  be a safety concern.&#xD;
&#xD;
              11. Any physical or psychiatric condition that in the Investigator's opinion would&#xD;
                  prevent adequate study participation.&#xD;
&#xD;
              12. Chronic medical condition that in the Investigator's opinion would affect study&#xD;
                  participation (such as uncontrolled hypertension, diabetes, hepatitis, HIV,&#xD;
                  etc.).&#xD;
&#xD;
              13. Diagnosis of:&#xD;
&#xD;
                    -  Cryoglobinemia&#xD;
&#xD;
                    -  Paroxysmal cold hemoglobinuria&#xD;
&#xD;
                    -  Cold Uticaria&#xD;
&#xD;
                    -  Raynaud's Disease&#xD;
&#xD;
                    -  Open and/or infected wounds&#xD;
&#xD;
                    -  Existing neuromuscular disease&#xD;
&#xD;
              14. Fitzpatrick Skin Type V or IV&#xD;
&#xD;
              15. Subject is currently enrolled in an investigational drug, biologic or device&#xD;
                  study that could affect the safety or effectiveness of the iovera° treatment.&#xD;
&#xD;
              16. Subject is known to be noncompliant or is unlikely to comply with the&#xD;
                  requirements of the study protocol in the opinion of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Aesthetics Research Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

